New amfAR issue briefs examine U.S. investment in global health, foreign aid

amfAR, The Foundation for AIDS Research, has published two new issue briefs examining U.S. investment in global health. The first (.pdf), titled "Saving Lives, Saving Money: The Case for Strengthened U.S. Investments in Global Health Programs," provides data on spending and program outcomes, concluding, "Although cuts in global health assistance would make only a miniscule contribution to deficit reduction, these cuts would have severe consequences for people living in the world's poorest countries." The second (.pdf), titled "The Evidence on U.S. Investments in Foreign Aid," says the small percentage the U.S. spends on foreign assistance "reduces poverty and promotes economic growth and international development"; "promotes America's security"; "is in America's economic interest"; "enhances U.S. diplomacy"; and receives bipartisan support. In addition, the issue brief notes the "effectiveness and efficiency of U.S. foreign aid is increasing" (March 2013).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study finds nirmatrelvir-ritonavir reduces severe COVID-19 and long COVID risks in high-risk patients